Drug Trial Radar · NCT05309460
Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial
Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Jun 20, 2022
Primary completion
May 1, 2024
Study completion Dec 1, 2024
Sponsor
- Lead sponsor
- Nebraska Methodist Health SystemAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Randomized trial comparing risk of hospital readmission and hypertensive complications between patients managed on Labetalol compared to Nifedipine.
Conditions
- Postpartum Preeclampsia
- Hypertension in Pregnancy
Interventions
Labetalol Oral TabletDrug
See Labetalol arm.
NIFEdipine ERDrug
See Nifedipine arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ReadmissionTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nebraska Methodist Women's Hospital
Omaha, Nebraska · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.